The stock of BioLineRx Ltd. (NASDAQ:BLRX) last traded at $0.67, down -1.18% from the previous session.
Data from the available sources indicates that BioLineRx Ltd. (NASDAQ:BLRX) is covered by 2 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $19.00 and a low of $4.00, we find $6.00. Given the previous closing price of $0.68, this indicates a potential upside of 782.35 percent. BLRX stock price is now 0.06% away from the 50-day moving average and -41.66% away from the 200-day moving average. The market capitalization of the company currently stands at $42.89M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
In total, 0 analysts have assigned it a hold rating, and 2 have given it a buy rating. Brokers who have rated the stock have averaged $9.67 as their price target over the next twelve months.
With the price target enhanced from $1 to $3, Maxim Group Upgraded its rating from Hold to Buy for BioLineRx Ltd. (NASDAQ: BLRX). On February 13, 2017, Rodman & Renshaw recently initiated its ‘Buy’ rating on the stock quoting a target price of $3, while ‘Maxim Group’ rates the stock as ‘Hold’.
There have been several recent changes in the stakes of large investors in BLRX stock. A new stake in BioLineRx Ltd. shares was purchased by ALTIUM CAPITAL MANAGEMENT LP during the first quarter worth $2,780,000. SABBY MANAGEMENT, LLC invested $2,033,000 in shares of BLRX during the first quarter. In the first quarter, ARMISTICE CAPITAL, LLC acquired a new stake in BioLineRx Ltd. valued at approximately $1,874,000. APOLLON WEALTH MANAGEMENT, LLC acquired a new stake in BLRX for approximately $33,000. TWO SIGMA SECURITIES, LLC purchased a new stake in BLRX valued at around $20,000 in the second quarter. In total, there are 33 active investors with 19.40% ownership of the company’s stock.
With an opening price of $0.6700 on Monday morning, BioLineRx Ltd. (NASDAQ: BLRX) set off the trading day. During the past 12 months, BioLineRx Ltd. has had a low of $0.55 and a high of $1.98. As of last week, the company has a debt-to-equity ratio of 0.20, a current ratio of 7.10, and a quick ratio of 7.10. The fifty day moving average price for BLRX is $0.6672 and a two-hundred day moving average price translates $1.1434 for the stock.
The latest earnings results from BioLineRx Ltd. (NASDAQ: BLRX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.15, missing analysts’ expectations of -$0.11 by -0.04. This compares to -$0.12 EPS in the same period last year. The company reported revenue of $7.08 million for the quarter, compared to $6.22 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 13.85 percent.
BioLineRx Ltd.(BLRX) Company Profile
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi’in, Israel.
